Hypoxia inducible factor 1α and 2α expression is independent of anemia in patients with stage I endometrial cancer

Anticancer Research

Volumn 22, Issue 6 C, 2002, Pages 4137-4140

  Koukourakis, M I ^a,b   Giatromanolaki, A ^a   Liberis, V ^a   Sivridis, E ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b Tumour/Angiogenesis Research Group   (Greece)

Author keywords

Anemia; Endometrial cancer; Hemoglobin; Hypoxia inducible factors alpha (HIF1 , HIF2 ; Radiotherapy; Vascular endothelial growth factor (VEGF)

Indexed keywords

HEMOGLOBIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANEMIA; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CELL TYPE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOMETRIUM CARCINOMA; FEMALE; GENETICS; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; MICROVASCULATURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ADENOCARCINOMA; ANEMIA; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; ENDOMETRIAL NEOPLASMS; ENDOTHELIAL GROWTH FACTORS; FEMALE; HEMOGLOBINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; NEOPLASM STAGING; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036876005     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Kumar P: Tumour hypoxia and anemia: impact on the efficacy of radiation therapy. Semin Hematol 37(4 Suppl 6): 4-8, 2000.
2. Chaplin DJ, Trotter MJ and Dougherty GJ: Microregional tumour blood flow: heterogeneity and therapeutic significance. In: Bicknell R, Lewis CE, Ferrara N (eds): Tumour Angiogenesis. Oxford, Oxford University Press, 1997, pp 61-70.
3. Koukourakis MI, Giatromanolaki A, Sivridis E and Fezoulidis I: Cancer vascularization: implications in radiotherapy? Int J Radiat Oncol Biol Phys 48: 545-553, 2000.
4. 2 homeostasis. Curr Opinion in Genet & Development 8: 588-594, 1998.
5. Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y and Fujii-Kuriyama Y: A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1α regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA 94: 4273-4278, 1997.
6. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D, Keshert E and Keshet E: Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394: 485-490, 1998.
7. Takagi H, King GL and Aiello LP: Hypoxia upregulates glucose transport activity through an adenosine-mediated increase of GLUT1 expression in retinal capillary endothelial cells. Diabetes 47: 1480-1488, 1998.
8. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL and Simons JW: Overexpression of Hypoxia-inducible factor 1a in common human cancers and their metastases. Cancer Res 59: 5830-5835, 1999.
9. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ and Harris AL: The expression and distribution of the hypoxia inducible factors HIF-1a and HIF-2a in normal human tissues, cancers and tumor associated macrophages. Am J PathoI 157: 411-421, 2000.
10. Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K, Pezzella F, Gatter KC and Harris AL: Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer 85: 881-890, 2001.
11. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G and Oberhuber G: Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 60: 4693-4696, 2000.
12. Vukovic V, Haugland HK, Nicklee T, Morrison AJ and Hedley DW: Hypoxia-inducible factor-1alpha is an intrinsic marker for hypoxia in cervical cancer xenografts. Cancer Res 61: 7394-7398, 2001.
13. Koukourakis MI, Giatromanolaki A, Skarlatos J, Corti L, Blandamura S, Piazza M, Gatter KC and Harris AL: Hypoxia Inducible Factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res 61: 1830-1832, 2001.
14. Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH and Semenza GL: Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61: 2911-2916, 2001.
15. Littbrand B and Revesz L: The effect of oxygen on cellular survival and recovery after irradiation. Br J Radiol 42: 914-924, 1969.
16. Sivridis E, Giatromanolaki A, Gatter KC, Harris AL and Koukourakis MI: Association of hypoxia inducible factor 1-alpha and 2-alpha with activated angiogenic pathways and prognosis in endometrial carcinomas. Cancer 95: 1055-1063, 2002.
17. Sivridis E, Giatromanolaki A, Anastasiadis P, Georgiou L, Gatter KC, Harris AL, Bicknell R and Koukourakis MI: Angiogenic cooperation of VEGF and stromal cell TP in endometrial carcinomas. J Pathol 196: 416-422, 2002.
18. Kelleher DK, Matthiensen U, Thews O and Vaupel P: Tumor oxygenation in anemic rats: effects of erythropoietin treatment versus red blood cell transfusion. Acta Oncol 34: 379-384, 1995.
19. Mazure NM, Chen EY, Laderoute KR and Giaccia AJ: Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-rastransformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 90: 3322-3331, 1997.
20. Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E, Gottschalk AR, Ryan HE, Johnson RS, Jefferson AB, Stokoe D and Giaccia AJ: Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14: 391-396, 2000.
21. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G and Semenza GL: Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res 59: 3915-3918, 1999.
22. Akakura N, Kobayashi M, Horiuchi I, Suzuki A, Wang J, Chen J, Niizeki H, Kawamura Ki, Hosokawa M and Asaka M: Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 61: 6548-6554, 2001.
23. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, Seetharam S, Koons A, Hari DM, Kufe DW and Weichselbaum RR: Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59: 3374-3378, 1999.
24. Brizel DM, Schroeder T, Scher RL, Walenta S, Clough RW, Dewhirst MW and Mueller-Klieser W: Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys 51: 349-353, 2001.
25. Dische S: What have we learned from hyperbaric oxygen? Radiother Oncol 20: 71-74, 1991.
26. Lee DJ, Cosmatos D, Marcial VA, Fu KK, Rotman M, Cooper JS, Ortiz HG, Beitler JJ, Abrams RA and Curran WJ: Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int J Radiat Oncol Biol Phys 32: 567-576, 1995.
27. Lee DJ, Fu KK, Cooper JS and Wasserman TH: End of an era or not? That is the question - in response to Dr. J. M. Brown Int J Radiat Oncol Biol Phys 32: 883-885, 1995.
28. Kung AL, Wang S, Klco JM, Kaelin WG and Livingston DM: Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med 6: 1335-1340, 2000.